Core Viewpoint - The acquisition of Shenzhen Huada Zhi Zao Technology Co., Ltd. (Huada Zhi Zao) of Shenzhen Huada Sanjian Qifa Technology Co., Ltd. and Hangzhou Huada Xufeng Technology Co., Ltd. for a total amount of 366 million yuan marks a strategic move to integrate cutting-edge technologies in spatial omics and nanopore sequencing, positioning the company as a unique player in the life sciences sector with a comprehensive product matrix covering "full-length sequencing + spatial omics" [1][2][3] Financial Considerations - The acquisition is deemed strategically valuable and cost-effective, with the target companies still in the incubation stage and not yet profitable, allowing for a valuation that reflects their actual business value [1][2] - The dynamic price-to-sales (PS) ratios of the target companies are around 3 times, significantly lower than comparable companies in their respective fields, indicating a favorable acquisition price [1] Long-term Strategic Layout - The integration of spatial omics with the existing DNBSEQ platform and nanopore sequencing will create a complete solution that enhances technical synergy and fulfills complex research needs, thereby increasing customer loyalty [2][3] - The acquisition will internalize core technologies, R&D teams, and intellectual property, establishing a unique technological barrier that supports long-term growth [3] Integration and Synergy Plans - Post-acquisition, the company plans to enhance collaboration across technology products, market channels, and operational management to achieve resource sharing and complementary advantages [4] - The company has achieved a 70% market share in the public tender market in China by 2025, which will support the growth of reagent consumption driven by installed instruments [5] Market and Channel Development - The target companies' customer bases align well with the existing product offerings, facilitating rapid business expansion and enhancing the company's market presence in various fields, including clinical applications and agricultural research [6] - The company has established a global marketing network covering over 110 countries and regions, which will enable quick integration and support for the target companies [6] Operational Management - The integration will leverage the high connectivity of the entire research, production, and sales chain, maximizing synergy and reinforcing the company's competitive edge in life science instruments and solutions [7] - The established supply chain and production capabilities will facilitate the production of the target companies' products, ensuring quality and cost-effectiveness [7]

Core Insights - The company reported a revenue of 3.013 billion yuan for 2024, marking a year-on-year growth of 3.48% [1] - The core gene sequencing instrument business generated revenue of 2.348 billion yuan, with a year-on-year increase of 2.47% [1] - The company showed resilience in a competitive global landscape, with a nearly 34% reduction in net profit loss year-on-year in the first quarter [1] Financial Performance - The domestic gene sequencing instrument revenue reached 1.607 billion yuan, reflecting an 11.37% year-on-year growth [1] - The first quarter saw a significant reduction in sales, management, and research expenses, which collectively decreased by 19% year-on-year [1] - The company achieved a 48.59% year-on-year increase in new sales installations of gene sequencing instruments globally [1] Market Position - The company maintained its position as the leader in new installations in the domestic market for three consecutive years, with a market share of 63.8% in 2024 [1] - The global market share for new installations increased by 9.5 percentage points to 28.2% compared to 2023 [1] Technological Advancements - The company has achieved a comprehensive strategic layout for three technical pathways in gene sequencing products, becoming the first globally to have large-scale commercial production of both short-read and long-read sequencing products [2] - Revenue from cell genomics increased by 171.98% year-on-year, with a nearly threefold growth in the Asia-Pacific region [2] - The integration of AI, biotechnology, and information technology has led to the deployment of AI models in the new Alpha Cube, supporting high-throughput sequencing needs [2] Industry Outlook - The company is expected to strengthen its leading position in the industry due to accelerated support from national policies and its self-controlled technology and supply chain systems [2] - The company is penetrating emerging scenarios such as clinical applications, disease control, environmental ecology, and agricultural breeding through continuous core technology research and multi-scenario applications [2]